Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation...

Full description

Saved in:
Bibliographic Details
Published in:Cancer immunity 2010-01, Vol.10, p.1-1
Main Authors: Yuan, Jianda, Page, David B, Ku, Geoffrey Y, Li, Yanyun, Mu, Zhenyu, Ariyan, Charlotte, Gallardo, Humilidad F, Roman, Ruth-Ann, Heine, Agnes I, Terzulli, Stephanie L, Ritter, Erika, Gnjatic, Sacha, Ritter, Gerd, Jungbluth, Achim A, Allison, James P, Old, Lloyd J, Wolchok, Jedd D
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Cell Count
Cell Separation
Female
Flow Cytometry
Humans
Immunohistochemistry
Ipilimumab
Lymphocytes - drug effects
Melanoma - drug therapy
Melanoma - immunology
Melanoma - secondary
Middle Aged
Skin Neoplasms - drug therapy
Skin Neoplasms - immunology
Skin Neoplasms - pathology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters.
ISSN:1424-9634